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An increasingly recognized mechanism of prostate cancer resistance is the transdifferentiation from ade-
nocarcinoma to treatment-emergent neuroendocrine prostate cancer (t-NEPC), an extremely aggressive
malignancy. The incidence of t-NEPC has been increasing in recent years, in part due to novel treatments
that target the androgen receptor pathway. While clinicians historically had very few options for t-NEPC
detection and treatment, recent research has uncovered key diagnostic tools and therapeutic targets that
can be translated into improved patient care. In this article, we will outline the clinical features of t-NEPC
and its molecular pathogenesis. Importantly, we will also discuss recently uncovered molecularly based
strategies aimed at improving the diagnosis and treatment of t-NEPC. Finally, we will propose a unified
algorithm that integrates clinical and molecular information for the clinical management of t-NEPC.
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Overview of treatment-emergent neuroendocrine prostate cancer
Prostate cancer (PCa) represents the most frequently diagnosed malignancy in men. In a large proportion of cases,
PCa can be detected prior to metastatic dissemination and, in such cases, treatments are initiated with curative
intent. Unfortunately, about 10–20% of patients will develop recurrence following these therapies or will present
with metastatic disease [1,2]. For these patients, the standard treatment is androgen-deprivation therapy, which
elicits a significant response in the vast majority of cases. However, a large proportion of patients under androgen-
deprivation therapy will develop castration-resistant prostate cancer (CRPC), a clinical entity that will require
further antiandrogen therapy and/or taxane-based chemotherapy. Studies have demonstrated that CRPC cells can
evade androgen receptor (AR) inhibition by several molecular mechanisms [3]. While some mechanisms are AR-
dependent and can be therefore counteracted by second-line hormonal therapies (abiraterone and enzalutamide),
increasing evidence suggests that hormonal resistance in the context of prolonged AR suppression can be mediated
by transdifferentiation of adenocarcinoma cells into treatment-emergent neuroendocrine prostate cancer (t-NEPC).
While neuroendocrine PCa may arise de novo, the large majority of cases occur in patients with CRPC that have
been treated with hormonal therapy and/or taxane-based chemotherapy [4]. Clinically, t-NEPC is an extremely
aggressive malignancy that is resistant to current therapies used in the context of advanced prostate adenocarcinoma.
In addition, t-NEPC displays high proliferative rates and tumor dissemination can occur quite rapidly [5]. Unlike
CRPC, which tends to produce osseous metastases, t-NEPC typically disseminates to visceral organs such as lung
and liver. Moreover, t-NEPC could be associated with distinct paraneoplastic syndromes, most notably hyper-
calcemia, Lambert-Eaton syndrome, Cushing’s syndrome and syndrome of inappropriate antidiuretic hormone
secretion [6]. However, it is worth noting that these syndromes are very rare and that no study has systematically
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evaluated their differential incidence in NEPC versus prostate adenocarcinoma patients. Histologically, t-NEPC
is usually characterized by small cells with prominent nucleus and limited cytoplasm that feature cytoplasmic
eosinophilic granules, hyperchromatic nucleus, salt-and-pepper chromatin and a high proliferative rate. The im-
munohistochemical profile of t-NEPC includes the expression of neuroendocrine markers such as synaptophysin
(SYP), chromogranin A (CHGA) and neuron-specific enolase (NSE), as well as absent AR and PSA expression [7,8].
Once considered a very rare occurrence, t-NEPC has become an increasingly recognized clinical problem. Recent
evidence indicates that approximately one out of six patients with progressive hormone-resistant PCa has NEPC [3].
In keeping with this evidence, autopsy studies have shown that neuroendocrine foci may be present in about 10–
20% of CRPC patients [6]. Given the extensive targeting of AR pathway and testosterone metabolism by recently
developed drugs [9,10], the incidence of t-NEPC is expected to rise significantly in the near future. Unfortunately,
t-NEPC is currently difficult to diagnose because it often arises in patients with multiple metastases, a condition
that usually discourages clinicians from performing biopsies. In addition, current clinical guidelines lack a consensus
definition of t-NEPC. As a result, the incidence of t-NEPC is usually underestimated and patients with undiagnosed
t-NEPC are treated unnecessarily with the same regimen as patients with AR-positive prostate adenocarcinoma,
with no success. Notably, preclinical and clinical evidence indicate that t-NEPC could be eminently sensitive
to selected chemotherapies and targeted drugs. Hence, an appropriate classification of t-NEPC cases can have a
transformative impact on patient treatment. Given the expected rise in t-NEPC incidence, it is imperative for
clinicians to increase efforts to diagnose t-NEPC early and provide optimal oncological management.
In recent years, numerous studies have addressed the molecular profile of t-NEPC. Increasing evidence suggest
that, while genetic mutations may contribute to its pathogenesis, t-NEPC is primarily driven by alterations that are
epigenetic in nature. In addition, recent research on t-NEPC has also uncovered aberrant tyrosine kinase activity
that can be therapeutically targeted. In this paper, we will critically discuss emerging evidence about the molecular
pathophysiology of t-NEPC with an emphasis on clinically actionable alterations. Based on this information, we
will also propose an integrated algorithm for the detection and management of t-NEPC in the context of advanced
PCa.
Molecular pathogenesis
AR signaling
While there have been documented cases of small cell prostate carcinomas arising in noncastrated patients (‘de
novo’ NEPC), the vast majority of patients present with t-NEPC following one or more cycles of hormonal therapy.
Multiple lines of evidence support the model that t-NEPC cells are clonally derived from prostate adenocarcinoma
cells. For instance, the frequency of TMPRSS-ERG fusion gene in CRPC closely resembles its frequency in NEPC,
thereby pointing toward a common origin [11]. In addition, androgen-sensitive prostate adenocarcinoma cells have
been shown to exhibit neuroendocrine differentiation in androgen-depleted cell medium [12], thereby implying
that castration may actively promote the development of t-NEPC. Further suggesting a conserved underlying
mechanism, reprogramming of normal prostate epithelial cells into neuroendocrine malignant cells has been
described [13]. Interestingly, a similar lung epithelial to neuroendocrine transdifferentiation was also documented
in the same manuscript [13]. Finally, xenograft experiments have shown that patient-derived xenografts from
primary PCa can undergo neuroendocrine transdifferentiation following androgen deprivation [14]. In this model,
androgen deprivation eliminates most but not all adenocarcinoma cells. The treatment-resistant adenocarcinoma
cells enter a dormant state and after several weeks acquire NEPC features and the ability to proliferate in androgen-
deprived conditions. Importantly, t-NEPC cells carry recurrent genetic and epigenetic alterations as an adaptive
response, thus suggesting that key molecular pathways controlling cell fate may be used as targets for therapeutic
intervention [14,15].
Genetic mutations
The advances in DNA sequencing have allowed an extensive genetic characterization of t-NEPC. Studies have shown
that genetic inactivation of the retinoblastoma (RB), p53 tumor suppressors and PTEN can be found in a majority
of t-NEPC cases [16–18]. While p53 and PTEN mutations are often present in CRPC, RB1 loss appears to be more
specific, since it was found in 90% of NEPC versus 15% of CRPC samples [16]. Other common genetic alterations in
t-NEPC involve the amplification of AURKA and MYCN proto-oncogenes, which are concurrently present in more
than 70% of metastatic t-NEPC cases versus 5% of unselected prostatic adenocarcinomas [19]. Notably, AURKA
inhibitors have been developed and are currently in clinical trials for the treatment of NEPC [20,21]. Aside from
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these mutations, it appears that there are few recurrent genetic alterations in t-NEPC. Since the neuroendocrine
transdifferentiation is an active process that arises as a result of androgen deprivation, we believe that a mechanism
that is not genetic but rather epigenetic is more probably the driving force in t-NEPC pathogenesis.
Epigenetic alterations
In addition to genetic mutations, epigenetic alterations have been well described in t-NEPC and appear to have
a driving effect on neuroendocrine differentiation. Epigenetics refers to all heritable changes in gene expression
that not attributed to changes in DNA sequence [22]. The drastic phenotypic transformation that drives t-NEPC is
thought to be mediated by specific changes in transcriptional patterns, consistent with epigenetic plasticity. From a
clinical standpoint, these driving epigenetic alterations may be used in the detection and pharmacological targeting
of t-NEPC. In the following sections, we will discuss the main epigenetic alterations that have been shown to drive
NEPC progression.
Polycomb group complexes
The most documented epigenetic alterations in t-NEPC have been the upregulation of the Polycomb group
(PcG) protein EZH2. As the catalytic subunit of the Polycomb repressive complex 2 (PRC2), EZH2 trimethylates
histone 3 at lysine 27 (H3K27me3) to induce gene silencing at target loci [23]. In t-NEPC, it has been shown
that EZH2 is upregulated and can repress specific tumor suppressive genes, thereby favoring neuroendocrine
transdifferentiation [24]. Furthermore, EZH2 has also been found to work in concert with N-Myc to promote
tumor aggressiveness in t-NEPC [25]. Importantly, pharmacologic inhibition of EZH2 via the small molecule 3-
deazaneplanocin A (DZNeP) has been shown inhibit the proliferation of AR-negative PCa in vitro and in vivo [26].
It should be noted that DZNeP has been subsequently identified as a broader histone methylase-inhibitor [27].
Hence, its effects on AR-negative PCa cells can be in part independent of EZH2 inhibition. More specific EZH2
inhibitors (e.g., tazemetostat) have shown promise for the treatment of refractory B-cell non-Hodgkin lymphoma
and other advanced solid tumors [28], but are yet to be tested on NEPC models and patients.
Another PcG protein that has been implicated in t-NEPC emergence is the chromodomain protein CBX2.
A member of the Polycomb repressive complex 1 (PRC1), CBX2 can directly bind to H3K27me3 via its chro-
modomain and further repress gene transcription at target loci, thereby acting as the bridge between PRC2 and
PRC1 [29]. Furthermore, CBX2 can also mediate chromatin compaction in a PRC2-independent manner [30]. CBX2
is overexpressed at both the mRNA and the protein level in t-NEPC [15]. These results have been corroborated by
a recent transcriptomic study comparing t-NEPC and CRPC clinical samples [3]. This study has shown that PRC2
components are among the top upregulated genes in t-NEPC.
In conclusion, it appears that aberrant PcG activity is a key feature of t-NEPC given the concurrent upregulation
of CBX2 and EZH2 that also correlates with consistent downregulation of PcG target genes [15]. Interestingly, in lung
cancer, CBX2 and EZH2 overexpression appears to be enriched in small cell carcinomas as opposed to non-small-
cell lung cancer, further suggesting that overexpression of these epigenetic regulators promotes neuroendocrine-like
phenotypes [15].
Heterochromatin proteins
Recently, a gene signature comprised of 36 heterochromatin-related genes has been shown to accurately distinguish
NEPC from adenocarcinoma, thereby paving the way for accurate NEPC diagnosis [31]. Within this gene signature,
HP1α has been described as an early driver of NEPC transdifferentiation and proliferation [31]. HP1-α is a
heterochromatic adaptor protein that can directly bind to histone H3K9me2/3 via its chromodomain and further
recruit other heterochromatin-associated proteins via its ‘chromoshadow’ domain, thereby triggering chromatin
compaction and gene silencing [32,33]. Interestingly, the epigenetic regulator DEK1, which controls heterochromatin
integrity by interacting with HP1-α, has been identified as a driver of t-NEPC emergence [34,35]. Several of the
36 heterochromatin genes, such as HP1b, HP1r, SUV39H1 and DNMT1, are upregulated at later stages of t-
NEPC transdifferentiation. All the aforementioned proteins have been described as HP1-α interactors [36–38]. These
consecutive and concurrent events suggest that an HP1-α-dependent mechanism drives the coordinated activation
of specific gene silencing programs in NEPC cells. Future investigations will need to identify the functional relevance
of HP1α-target genes in NEPC cells.
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Noncoding RNAs
An important component of the cell’s epigenetic machinery is constituted by noncoding RNAs (ncRNAs), in other
words, transcripts that are not translated into proteins but regulate important cellular functions by interacting with
specific macromolecules. Deep sequencing analyses have revealed that ncRNAs represent the vast majority of the
human cell’s transcriptome [39]. Importantly, ncRNAs orchestrate the coordinated activation of gene expression
programs, thereby controlling cell differentiation, cell motility and other cancer-relevant phenotypes [40]. Given this
background, it is not surprising that selected ncRNAs have been identified as drivers of t-NEPC transformation.
The most studied class of ncRNAs in this context is represented by miRNAs, short transcripts that bind specific
mRNAs and inhibit their translation [41]. For example, an in vitro screening of miRNAs expressed during the
transdifferentiation of prostate adenocarcinoma cells into NEPC cells has shown that this process is driven by the
downregulation of mir-17 and by the concurrent activation of its target, cyclin D1 [42]. A recent transcriptomic
analysis of a murine NEPC model has identified two groups of microRNAs that drive different stages of the disease:
when the cancer is localized to the prostate, a set of miRNAs activate Akt-dependent cell proliferation and survival;
when the NEPC cells invade distant organs, a completely different miRNA signature is activated to suppress Akt
activity and activate the epithelial-to-mesenchymal transition [43]. Notably, our studies on patient-derived xenografts
confirmed the centrality of this pathway in advanced PCa; we have found that mir-100-dependent inhibition of
mTOR (an indirect target of AKT) facilitates the postcastration survival of both CRPC and NEPC cells [44].
Another important component of the ‘noncoding transcriptome’ is represented by long ncRNAs (lncRNAs),
which are defined as nonprotein-coding transcripts longer than 200bp. It is well established that these transcripts
fold in tridimensional structures and interact with macromolecules in several ways, thereby controlling key cellular
functions [40]. The role of lncRNAs in NEPC is still largely undefined but a few important players are emerging.
A preliminary analysis of microarray and clinical data has identified the long ncRNA MIAT as an NEPC-specific
transcript, whose expression is associated with poor prognosis [45]. Notably, MIAT is emerging as an oncogenic
lncRNA in other neoplasms [46]. More recently, a large bioinformatic study has identified additional lncRNAs
that are specifically expressed in NEPC cells. These include well-known oncogenic transcripts (e.g., H19) and
several uncharacterized lncRNAs [47]. Further functional studies are needed to identify the mechanism of action of
these NEPC-associated lncRNAs, as well as their translational relevance. Indeed, the expression of some lncRNAs
is highly tissue- and disease-specific, making them ideal candidates for the development of noninvasive NEPC
biomarkers [48].
Tumor microenvironment
While the genome and transcriptome of t-NEPC has been heavily investigated, recent evidence suggests that the
tumor microenvironment may also harbor specific extracellular alterations that favor neuroendocrine differentiation
and tumor dissemination. For instance, it appears that an acidic extracellular pH plays a role in t-NEPC cell survival
as reduction in lactic acid secretion via MCT4 inhibition decreased t-NEPC cell viability [49]. The presence of
stromal cells also plays a role in t-NEPC development, particularly for cancer-associated fibroblasts (CAFs). It has
been demonstrated that heterogeneous populations of CAFs, characterized by alterations in SFRP1 and CD105,
can directly induce neuroendocrine differentiation [50]. In keeping with this evidence, it was shown that epigenetic
alterations in CAFs can induce a microenvironment that favors the neuroendocrine phenotype [51]. In addition, a
prostaglandin-dependent inflammatory response has been shown to contribute to NEPC progression [52]. On the
other hand, tumor infiltrating mast cells have been shown to inhibit NEPC transdifferentiation in vivo, possibly
by reducing the local availability of stem cell factor [53].
Taken together, this evidence suggests that several adaptive molecular alterations occurring in the tumor microen-
vironment can trigger specific signal transduction pathways and epigenetic programs, thereby favoring t-NEPC
initiation and progression. We have summarized this integrated molecular model of NEPC initiation in Figure 1.
Screening & diagnosis
Initial prostate biopsy
As previously discussed, NEPC may present de novo as a primary prostate malignancy, although this presentation
remains very rare. In most cases, t-NEPC seems to rise from the transdifferentiation of prostate adenocarcinoma
in patients exposed to prolonged hormonal therapy. However, as very few lesions are biopsied in these patients
with advanced disease, t-NEPC is often underdiagnosed, no t-NEPC effective treatment is initiated and this causes
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Figure 1. Molecular mechanisms involved in neuroendocrine prostate cancer pathogenesis. ADT: Androgen-deprivation therapy; AR:
Androgen receptor; ncRNA: non-coding RNA; NEPC: Neuroendocrine prostate cancer; PCa: Prostate cancer.
rapid patient decline and death. Thus, it is imperative to identify and implement methods that can provide a fast
and accurate diagnosis of t-NEPC.
It appears that some prostate adenocarcinomas are intrinsically predisposed to undergo neuroendocrine transdif-
ferentiation because of their molecular profile. Studies in patient-derived xenograft models have shown that specific
tumors can recurrently evolve to t-NEPC upon androgen deprivation, while others never transdifferentiate under
the same conditions [14]. This implies that identifying the molecular alterations that predispose for neuroendocrine
transdifferentiation could provide an estimated risk of developing t-NEPC. At present, no molecular alteration
present in primary PCa is known to predict t-NEPC emergence upon androgen deprivation. However, further
genomic and transcriptomic studies should explore this avenue since it would provide important information that
allows earlier detection and treatment of t-NEPC.
Biopsy of metastatic tissues
Histological examination is currently the only method by which NEPC can be diagnosed. Almost all t-NEPC
cases are characterized by extensive metastatic dissemination. Biopsies are rarely conducted in metastatic PCa cases
because it is generally believed that the risks associated with this invasive procedure outweigh the possible benefits
to the patient. However, we argue that biopsies should be performed more frequently and systematically in patients
with advanced prostatic disease that present atypical progression for at least three reasons. First, t-NEPC generally
carries a poorer prognosis than classical CRPC and does not respond to second-line hormonal therapies (abiraterone
and enzalutamide). Since t-NEPC is intrinsically resistant to hormonal treatment, its early diagnosis can reduce
the number of ineffective treatments targeting the AR axis, thereby reducing unnecessary costs and side effects.
Second, the incidence of t-NEPC is increasing and is predicted to rise even more in the coming years [4]. Third, and
most importantly, NEPC is more susceptible to chemotherapy regimens that are usually not employed in CRPC
patients. In addition, some NEPC-targeted therapies are already in clinical trials and many more are investigated in
preclinical models, thereby allowing unprecedented therapeutic options for this aggressive malignancy. For all these
reasons, we strongly encourage clinicians to consider biopsy of progressing lesions that present atypical patterns.
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An important notion to define is what to consider an atypical progression that warrants a biopsy. As previously
stated, t-NEPC cells are AR-negative and do not express PSA. Thus, new metastatic nodules or rapidly progressing
lesions without a proportional rise in PSA should prompt suspicion for t-NEPC. Another important difference
between prostate adenocarcinoma and t-NEPC is the pattern of dissemination, as adenocarcinoma typically
produces bone metastases while t-NEPC disseminates in visceral organs. Therefore, we recommend that visceral
metastases in patients with CRPC should preferentially undergo biopsy of these metastases, especially if they occur
without a proportional increase in PSA levels. Finally, another legitimate indication for biopsy is the presence of
paraneoplastic syndromes associated with t-NEPC such as hypercalcemia, Lambert-Eaton syndrome, Cushing’s
syndrome and syndrome of inappropriate antidiuretic hormone secretion [6]. We believe all three of these clinical
scenarios in a CRPC patient exposed to multiple lines of hormonal therapy should be considered ‘red flags’ for
t-NEPC development and therefore warrant further investigation. As we will see in the following paragraphs,
noninvasive diagnostic methodologies can be employed in the current clinical setting or in the near future to
further stratify patients at risk of developing t-NEPC, thereby guiding the clinician’s decision on when and if a
biopsy should be performed.
Imaging
Imaging is a major technology for PCa detection [54]. The most commonly employed imaging methodologies are
US, MRI and PET. Multiparametric US and MRI scans, in which different detection modalities are combined,
have been shown to significantly improve the detection rate of PCas, when compared with conventional diagnostic
strategies [55]. However, none of these technologies are currently able to distinguish prostatic adenocarcinomas
from NEPCs. The use of artificial intelligence could improve the discriminatory power of these techniques in the
future [56], thereby enabling the clinicians to perform noninvasive histologic analyses that would revolutionize the
management of NEPC. However, until the technology is mature for these developments, MRI and ultrasound
utility will be limited to performing guided biopsies and to identify visceral metastases, which are more frequently,
but not exclusively, associated with NEPC.
Another interesting application of imaging techniques is the detection of metabolically active cancers using 2-
deoxy-2-[fluorine-18]fluoro-D-glucose (FDG) PET scans, usually in combination with CT scans. These techniques
proved to be an independent predictor of hormonal treatment failure in patients with metastatic CRPC. It would
be intriguing to test the efficacy of this technique, possibly combined with other biomarkers, in detecting t-NEPC
cases.
PET scans are less frequently used in the clinical setting, but they provide crucial information about the metabolic,
cellular and molecular activity of cancer cells [57]. Of particular interest is the use of PET-based radiotracers that
bind specifically PCa antigens. Clinical studies have successfully used radiolabeled antibodies or small molecule
inhibitors of PSMA, a membrane protein overexpressed by PCa cells [58]. Since NEPCs are characterized by the
specific expression of proteins such as CD56 and CHGA, it is conceivable that this technology will be adapted to
the detection and localization of NEPCs in the coming years.
Taken together, this evidence indicates that multimodal US and MRI can already be used in the clinical setting
to improve the accuracy of biopsies aimed at detecting t-NEPC. In the near future, we expect that targeted PET
scans could represent a valuable, less invasive diagnostic tool.
Serum markers
The use of serum biomarkers, alone or in combination with imaging techniques, could provide an opportunity
for noninvasive detection of t-NEPC as well as for monitoring of t-NEPC emergence in PCa patients treated with
first- and second-line hormonal therapies. Four protein markers are currently used for the histological detection
of NEPCs: CHGA, CD56, NSE and SYP [8]. All these markers can be detected by commonly used techniques
(e.g., ELISA) in the serum of PCa patients. However, CHGA and NSE represent the most extensively studied serum
biomarkers for NEPC detection and monitoring. Both CHGA and NSE seem to be progressively upregulated in
serum samples of PCa patients exposed to hormonal therapies [59]. In addition, higher CHGA/NSE serum levels
before abiraterone/enzalutamide treatment, or the elevation of these markers during the first 3 months of abiraterone
treatment, are independent predictors of poorer clinical outcomes [60,61]. These results have been partially confirmed
by a study showing that post-treatment elevation of serum CHGA levels predicts shorter progression-free survival
(PFS) in CRPC patients treated with abiraterone [62]. Taken together, this evidence indicates that serum CGHA
and/or NSE levels can be used to identify CRPC adenocarcinomas which transdifferentiate to NEPC during second-
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line hormonal treatments. The evidence seems to be stronger for abiraterone and should be further confirmed in
enzalutamide-treated patients.
Although these results are encouraging and in line with preclinical evidence on t-NEPC, the specificity and
sensitivity of circulating NEPC protein biomarkers needs to be further tested. For example, a recent study showed
that the serum expression of CHGA is unable to discriminate NEPC versus CRPC patients [3]. While serum NSE
expression was significantly higher in NEPC versus CRPC patients, this marker showed a wide range of expression
levels (5–90 ng/ml in the NEPC group vs 1–83 ng/ml in the CRPC group). This observation indicates that basal
serum levels of NSE and CHGA cannot be used as reliable markers for t-NEPC detection. In addition, it should
be noted that patients taking proton pump inhibitors have abnormally elevated circulating CHGA levels in the
absence of neuroendocrine tumors. However, there is consistent evidence showing that an increase in CHGA and
NSE predicts abiraterone resistance, and probably t-NEPC emergence in CRPC patients.
In addition to protein biomarkers, circulating nucleic acids can be used to improve the detection and monitoring
of t-NEPC. As we have discussed, NEPC is characterized by a higher rate of mutations and gene copy number
variations at specific loci. Hence, it is conceivable that these alterations can be detected in circulating tumor DNA
(ctDNA). A recent study on enzalutamide- and abiraterone-resistant patients found that highly complex ctDNA
signatures are associated with the emergence of treatment resistance [63]. So far, these findings have not been
replicated by independent studies and it is not clear whether these complex signatures can be readily translated into
the clinical setting. In addition, this study did not identify t-NEPC-specific ctDNA alterations. More promising
results could come from the detection of NEPC-specific ncRNAs in serum samples, an approach that has been
already used successfully to detect CRPC cases [64]. As our understanding of t-NEPC biology advances, we expect
that more specific DNA and noncoding RNA biomarkers will emerge and be tested in clinical trials to improve the
diagnostic and prognostic accuracy of serum NSE and CHGA.
Circulating tumor cells
Detection of neuroendocrine transformation of CRPC is currently dependent on tumor biopsy. Although tissue
evaluation is the ‘gold standard’ diagnostic modality, access to tumor tissue is often very limited in this disease due
to the nature of the metastases (often in visceral locations or bones), their location (pelvic or peri-vascular nodes),
paucity and quality of tissue, in addition to morbidity from the biopsy procedure. Therefore, NEPC detection
using minimally invasive blood-based markers would have high utility and allow longitudinal sampling in CRPC
patients to provide early evidence of transdifferentiation to NEPC.
There is increasing evidence that circulating tumor cells (CTCs) in blood often indicate metastatic disease and
have clinical potential as monitoring tools, prognostic markers, predictors of treatment efficacy including PFS
and overall survival (OS). Their potential utility is very obvious as minimally invasive, real-time liquid bioassays
with the possibility of representative characterization of early or advanced PCas at various stages and over time.
From initial simple enumeration studies, there has been rapid technological progress to allow capture, enrichment
and propagation of CTCs for downstream analyses including short-term cultures and ex vivo drug-sensitivity
testing, single cell sorting of CTCs by fluorescence activated cell sorting, generation of xenografts, next generation
sequencing, gene expression profiling, gene copy number determination and epigenomic analyses. Thus, CTCs can
provide detailed phenotypic and molecular insights into progressive malignancies [64,65].
However, the key limitations of CTC based biomarker development include the extreme rarity of CTCs in blood
(few as 1 in 109 blood cells), the variability in their size, shape and phenotypic markers. Technologies designed to
isolate these cells [66] address the issues of recovery/isolation (enumeration), rate of throughput (volume of blood
needed), purity (contamination with other cells) and clinical relevance (biological and therapeutic information
obtained). The CTC isolation technologies currently available include antibody capture through expression of the
cell adhesion molecule epithelial cell adhesion molecule, either through antibody-coated magnetic nanoparticles
(CellSearch) or affinity based microfluidic devices (CTC Chip, Herringbone Chip, GO Chip). Other approaches
avoid antibody-binding and allow for in situ staining or tumor cell recovery for analysis and include isolation
by size of epithelia tumor through a filtration process, inertial based separation, Dean flow fractionation and
dielectrophoresis [66].
Currently, the only test for CTC detection and enumeration with regulatory approval is based on immuno-
magnetic enrichment of CTCs (CellSearch) expressing the epithelial cell adhesion molecule. CTC detection by
CellSearch is prognostic for most men with metastatic PCa. CTC levels post-treatment with serial blood monitoring
was associated with improved survival and reflected concurrent radiological responses and often predated falls in
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PSA [67,68]. Two recent studies have addressed the potential utility of CTCs in NEPC. In both studies, NEPC
transformation was confirmed by histology of a metastatic biopsy. The first, retrospectively, identified men with
CRPC and available CTC enumeration (by CellSearch) and compared counts/7.5 ml blood with OS, measured
from the first recorded CTC count until death or last follow-up. In 61 patients, (21 NEPC; 40 CRPC) the rate of
detectable CTC counts was similar for the two groups (47.6% of NEPC and 55% of CRPC). The detection of 0–4
CTCs in NEPC was associated with a median OS of 22.6 versus 6.6 months in patients with ≥5 CTCs (p = 0.001).
The authors concluded that CTC counts appeared to be prognostic for both NEPC and CRPC groups [69].
A further study used CellSearch and compared this with an alternative, nonselection bias platform (Epic
Sciences; CA, USA) that characterizes all nucleated cells and identifies CTCs based on multiparametric digital
reading of protein expression and cell morphology [70]. Epic identified distinct CTC populations and highlighted
phenotypically heterogeneous CTCs from metastatic PCa patients. The study also used an additional molecular
characterisation of these CTCs using FISH for AURKA, a gene commonly amplified in NEPC [71], showing
concordance with matched metastatic biopsies. In selected cases CTCs were isolated from six patients using
CellSearch and from all 17 NEPC patients with the Epic platform. NEPC-CTCs did express typical markers such
as CHGA and SYP, but these were predominantly of smaller size compared with CRPC-CTCs and had lower
AR expression as well as abnormal nuclear and cytoplasmic features. CRPC-CTCs also expressed lower levels of
epithelial cytokeratins, possibly as a consequence of the epithelial-to-mesenchymal transition that can occur during
metastasis and drug resistance [72,73]. These two studies have shown the enormous potential utility of CTC as serial
monitoring tools in men at risk of NEPC following resistance and progression after AR-directed therapies for their
CRPC. Further prospective studies should explore the clinical utility of routine CTC monitoring in the early and
noninvasive detection of NEPC transdifferentiation.
Therapeutic avenues
Despite significant progress in defining and detecting NEPC, research has not yet led to improvements in treatment
outcomes. To date, treatment for confirmed or suspected NEPC is a platinum-based regimen similar to those em-
ployed for the treatment of other neuroendocrine small cell carcinomas. These regimens have been studied in clinical
trials for ‘variant’ and ‘anaplastic’ CRPCs, both of which are definitions that partially overlap with NEPC [71,72]. In
these patients, response rates to cisplatin/carboplatin combinations with either docetaxel or etoposide are relatively
high, but not durable. Addition of further conventional chemotherapeutics such as anthracyclines has not proven
advantageous and has just increased toxicity [74]. In light of the increasingly recognized importance of t-NEPC, we
believe that clinical trials specifically designed to identify the optimal composition and sequence of chemotherapy
regimens in this cohort should be implemented as soon as possible.
In the more distant future, targeted therapies could substantially improve clinical outcomes in t-NEPC patients.
Recent studies have shown that both the aurora kinase A (AURKA) protein is highly expressed and the AURKA
gene amplified in NEPC [75]. Similarly, the N-myc proto-oncogene (MYCN) is both amplified and overexpressed in
NEPC [19]. Subsequently, there is evidence that these proteins can cooperate and drive neuroendocrine transforma-
tion. Preclinical testing of an AURKA inhibitor, potentially also indirectly targeting N-myc, resulted in significant
antitumor effects [75]. This has led to evaluation of alisertib, an AURKA inhibitor, in a Phase II clinical trial in
patients with NEPC. Even though the study did not meet its primary end point of increased radiographic PFS, a
subset of patients with activation of AURKA and N-Myc seemed to benefit from alisertib treatment [21]. We believe
that these interesting results should be confirmed by a prospective study selectively enrolling NEPC patients with
AURKA and N-Myc activation. The importance of N-Myc as a predictive marker is further highlighted by a recent
study, which has identified a novel N-Myc–PARP–DNA damage response pathway in a subset of CRPC NEPC
patients [76]. Using drugs already developed, this pathway may provide a further therapeutic opportunity in this
disease [76].
As we have discussed, preclinical and clinical studies indicate that Polycomb genes are key drivers of t-NEPC
initiation and progression. In this context, three EZH2 small molecule inhibitors (tazemetostat, GSK126 and
CP-1205) are the most developed compounds. These three drugs have entered Phase I and II clinical trials for
solid and hematologic malignancies [77]. Notably, a Phase I/II clinical trial is testing the combination of CP-1205
and abiraterone or enzalutamide in patients with metastatic CRPC (NCT03480646). In this context, it would be
interesting to investigate whether CP1205 treatment suppresses the increase in CHGA/NSE serum levels, which
is induced by second-line hormonal therapies [60], and if this phenomenon is accompanied by an enhanced efficacy
of abiraterone and/or enzalutamide.
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Clinical progression Proposed NEPC management algorithm
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If t-NEPC is diagnosed, current and future treatment options include:
a) Rapidly-progressing lesions without proportional PSA rise
b) Molecular alterations predicting future t-NEPC incidence
a) De novo NEPC (CHGA, SYP, NSE)
a) Serum markers (CHGA, NSE)
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Figure 2. Clinical progression and proposed neuroendocrine prostate cancer management algorithm.
ADT: Androgen-deprivation therapy; CTC: Circulating tumor cell; NEPC: Neuroendocrine prostate cancer.
Recently, there has been an interest in developing small molecule inhibitors of chromodomain-containing proteins
such as the CBX proteins. Chromodomains bind to specific methylated lysine residues on histone proteins [78].
Therefore, by designing small molecules that can disrupt this interaction can interfere with the recruitment of
aberrant epigenetic complexes such as PRC1 in the case of CBX proteins [79,80]. At this point, chromodomain
inhibitors are only in preclinical testing, but some have demonstrated protein-specific activity with submicromolar
affinity [81–84]. Given the involvement of CBX2 and HP1-α in t-NEPC pathogenesis [15,31], the development of
chromodomain inhibitors may hold great promise for the treatment of neuroendocrine disease.
Taken together, this evidence suggests that in the near future clinicians will be able to treat t-NEPC patients
with novel, more effective regimens, which could comprise both chemotherapy and targeted therapies. Within the
NEPC cohort, patients could be stratified based on molecular markers and therefore assigned to a specific targeted
treatment (e.g., EZH2 vs AURKA inhibitor).
A proposed algorithm of clinical management
Based on the literature discussed above, we propose a unified set of clinical guidelines for the management of NEPC
(Figure 2). We believe that these guidelines are a work in progress, which will become more and more prescriptive
with the identification of new biomarkers and effective therapies. For this reason, we have differentiated the clinical
interventions based on three levels of evidence: interventions that are currently feasible in the clinical setting,
interventions that have been proven useful in at least two clinical studies and interventions that are currently being
investigated in preclinical models.
At initial biopsy, pathological examination of the prostate should always include the immunohistochemical
markers of NEPC, such as CHGA, SYP and NSE. This allows the detection of de novo NEPC, which accounts for
about 5% of prostate neoplasms and is resistant to localized PCa therapies and carries a much poorer prognosis [85].
Recent studies have shown that specific PCa types may be predisposed to undergo neuroendocrine transdifferen-
tiation upon hormonal therapy [14]. Thus, mutations or gene signatures in primary PCa that can identify such
patients represent important clinical tools that are currently under investigation.
Throughout the sequential progression of PCa, clinicians should always be on the lookout for t-NEPC and
should consider biopsy whenever they suspect that t-NEPC may be present after evaluating the risks and benefits.
future science group 10.2217/ije-2019-0008
Review Clermont, Ci, Pandha, Wang & Crea
In particular, rapidly progressing lesions without a proportional PSA rise, in patients exposed to hormonal therapies,
should prompt biopsy. Furthermore, biopsy should also be considered in CRPC patients with visceral metastases or
NEPC-associated paraneoplastic syndromes such as those previously mentioned. Finally, clinicians should consider
biopsy in the context of elevated serum markers such as CHGA and NSE. Although a baseline measurement of
these markers does not carry high sensitivity [86], clinical studies indicate that an increase in circulating NEPC
levels during hormonal therapy is more indicative of transdifferentiation and treatment resistance [60,61]. Hence,
we believe that this hypothesis should be tested in prospective clinical trials and implemented in the clinical setting
if confirmed. Currently, the analysis of CTCs or circulating tumor DNA/RNA has yet to become integrated in
routine clinical practice, but we believe that these technologies hold great promise for the noninvasive monitoring
of t-NEPC [70].
When t-NEPC has been confirmed, the first-line treatment should consist of platinum-based chemotherapy [6].
Unfortunately, this regimen does not lead to long-term remission and carries significant toxicity [6]. There are
currently a number of drugs in development for t-NEPC but only Alisertib has been evaluated in clinical testing.
We propose that specific pharmacogenetics tests should be designed in clinical trials evaluating the activity and
efficacy of experimental targeted therapies. If these trials lead to positive results, platinum-based regimens could
be rapidly associated with individualized targeted treatments. In conclusion, we believe that a combination of
innovative diagnostic and therapeutic methods will lead to the rapid identification and effective treatment of
t-NEPC, an underdiagnosed and lethal disease.
Conclusion
In conclusion, t-NEPC represents an extremely aggressive malignancy that occurs as a result of pharmacological
targeting of the AR axis. With the recent introduction of novel hormonal treatments that potently suppress AR
signaling and extend OS in CRPC patients, it is anticipated that the incidence of NEPC will rise in the near
future. Thus, it is critical to provide clinicians with adequate tools to improve the clinical management of this
lethal disease. Recent research has uncovered insights into the molecular pathophysiology of t-NEPC that may
be translated into better diagnostic and therapeutic options. Although there remains some controversy within
the definition of t-NEPC, this article provides an up-to-date summary of the literature addressing this emerging
malignancy and provide the basis for its molecularly driven clinical management.
Future perspective
Emerging preclinical and clinical evidence corroborate the hypothesis that t-NEPC is a distinct clinical entity, which
will require new diagnostic and therapeutic interventions. In this review, we have proposed a clinical algorithm
to address this new clinical entity with currently available methodologies. However, we believe that, in the near
future, the following challenges should be addressed by a concerted effort involving oncologists, pathologists and
preclinical scientists:
• There is still no consensus definition of t-NEPC. Some pathologists call this type of PCa ‘anaplastic’ or ‘variant’.
Hence, we think that a consensus conference involving leaders in the field from different disciplines should be
organized to identify a shared working definition of t-NEPC
• Despite the presence of reliable tissue markers of t-NEPC, more work should be devoted to the identification
of reliable circulating biomarkers. We believe that noncoding RNAs are particularly promising in this area
• Current treatment of t-NEPC is restricted to palliative chemotherapy. New agents (e.g., EZH2 inhibitors)
should be tested in preclinical and subsequently clinical studies specifically designed for this type of malignancy
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Executive summary
• Overview: treatment-emergent neuroendocrine prostate cancer (t-NEPC) is an extremely lethal cancer that arises
as a consequence of neuroendocrine transdifferentiation secondary to hormonal treatments in men with
castration-resistant prostate cancer.
• Molecular pathogenesis: while very few genetic mutations can be recurrently found in t-NEPC, increasing
evidence suggests that the pathophysiology of t-NEPC is epigenetic in nature and involves notably chromatin
regulators and noncoding RNA.
• Screening and diagnosis: at present, diagnosis of t-NEPC is made on the basis of pathological findings of
neuroendocrine differentiation in prostate tumors (local or metastatic) that have undergone hormonal
treatment. Because this requires a biopsy and that few biopsies are performed in this clinical setting, t-NEPC is
currently underdiagnosed. However, there are currently efforts to develop noninvasive methods of screening
based on circulating tumor RNA/DNA, circulating tumor cells as well as imaging, notably using PET scans.
• Therapeutic avenues: classically, t-NEPC has been treated with platinum-based chemotherapy but unfortunately
the oncological improvement is usually minimal with significant side effects. To date, the most advanced
molecularly targeted therapy in clinical testing is alisertib (Phase II), an aurora kinase A kinase inhibitor. Other
potential drug targets in investigation include MYCN, EZH2, CBX2 and HP1-α.
• Proposed clinical algorithm: integrating the latest clinical and preclinical data, we elaborate a set of clinical
guidelines for the management of t-NEPC from its initial detection in patients with known prostate
adenocarcinoma to its diagnosis and treatment.
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